De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
SBS Overzicht aandelen
Stratec SE ontwerpt en produceert samen met haar dochterondernemingen automatiserings- en instrumentatieoplossingen op het gebied van in-vitro diagnostiek en biowetenschappen in Duitsland, de Europese Unie en internationaal.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 3/6 |
Stratec SE Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €43.50 |
| 52 Week Hoogtepunt | €49.65 |
| 52 Week Laag | €36.00 |
| Bèta | 0.16 |
| 11 maand verandering | -0.57% |
| 3 maanden verandering | -6.15% |
| 1 Jaar Verandering | 1.64% |
| 33 jaar verandering | -63.51% |
| 5 jaar verandering | -43.43% |
| Verandering sinds IPO | 736.05% |
Recent nieuws en updates
Recent updates
Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
May 11
Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Apr 11Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Apr 01Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
Mar 28Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Dec 21Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 03We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Oct 19Return Trends At Stratec (ETR:SBS) Aren't Appealing
Jul 12Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Jun 27Is Stratec (ETR:SBS) Using Too Much Debt?
May 25Stratec's (ETR:SBS) Upcoming Dividend Will Be Larger Than Last Year's
Apr 02The Returns At Stratec (ETR:SBS) Aren't Growing
Jan 28Calculating The Fair Value Of Stratec SE (ETR:SBS)
Jan 12Is Stratec (ETR:SBS) A Risky Investment?
Oct 26Returns On Capital At Stratec (ETR:SBS) Have Stalled
Oct 11Stratec (ETR:SBS) Has A Pretty Healthy Balance Sheet
Jul 23Should You Be Adding Stratec (ETR:SBS) To Your Watchlist Today?
Jul 07Stratec's (ETR:SBS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 12Stratec (ETR:SBS) Has Announced That It Will Be Increasing Its Dividend To €0.95
Apr 28Analysts Are Updating Their Stratec SE (ETR:SBS) Estimates After Its Annual Results
Apr 03Stratec's (ETR:SBS) Dividend Will Be Increased To €0.95
Apr 02These 4 Measures Indicate That Stratec (ETR:SBS) Is Using Debt Reasonably Well
Mar 13Stratec (ETR:SBS) Is Doing The Right Things To Multiply Its Share Price
Feb 12Do Stratec's (ETR:SBS) Earnings Warrant Your Attention?
Jan 27We Think Stratec (ETR:SBS) Can Stay On Top Of Its Debt
Dec 05Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Nov 02Do Stratec's (ETR:SBS) Earnings Warrant Your Attention?
Oct 18Is Stratec (ETR:SBS) Using Too Much Debt?
Sep 03Stratec (ETR:SBS) Will Want To Turn Around Its Return Trends
Aug 03Should You Be Adding Stratec (ETR:SBS) To Your Watchlist Today?
Jul 20Calculating The Intrinsic Value Of Stratec SE (ETR:SBS)
Jun 14Here's Why Stratec (ETR:SBS) Can Manage Its Debt Responsibly
May 31Here's Why Shareholders Will Not Be Complaining About Stratec SE's (ETR:SBS) CEO Pay Packet
May 13Rendement voor aandeelhouders
| SBS | DE Medical Equipment | DE Markt | |
|---|---|---|---|
| 7D | 0.2% | 8.4% | 1.8% |
| 1Y | 1.6% | 8.3% | 13.8% |
Rendement versus industrie: SBS underperformed the German Medical Equipment industry which returned 9.5% over the past year.
Rendement versus markt: SBS underperformed the German Market which returned 13.3% over the past year.
Prijsvolatiliteit
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stabiele aandelenkoers: SBS has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: SBS's weekly volatility (5%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1979 | 1,464 | Marcus Wolfinger | www.stratec.com |
Stratec SE ontwerpt en produceert samen met haar dochterondernemingen automatiserings- en instrumentatieoplossingen op het gebied van in-vitro diagnostiek en biowetenschappen in Duitsland, de Europese Unie en internationaal. Het ontwerpt en produceert geautomatiseerde analysesystemen voor klanten in de klinische diagnostiek en biotechnologie en biedt complexe verbruiksgoederen voor diagnostiek en medische toepassingen. Het bedrijf was voorheen bekend als STRATEC Biomedical AG en veranderde zijn naam in Stratec SE in december 2018.
Stratec SE Samenvatting
| SBS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €528.78m |
| Inkomsten(TTM) | €14.58m |
| Inkomsten(TTM) | €255.98m |
36.3x
Koers/Winstverhouding2.1x
P/S-verhoudingIs SBS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SBS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €255.98m |
| Kosten van inkomsten | €186.66m |
| Brutowinst | €69.33m |
| Overige uitgaven | €54.75m |
| Inkomsten | €14.58m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
Oct 25, 2024
| Winst per aandeel (EPS) | 1.20 |
| Brutomarge | 27.08% |
| Nettowinstmarge | 5.69% |
| Schuld/Eigen Vermogen Verhouding | 66.0% |
Hoe presteerde SBS op de lange termijn?
Bekijk historische prestaties en vergelijking